23andMe, Genentech partner on Parkinson's

23andMe Inc. (Mountain View, Calif.) partnered with the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) in a multi-year deal to identify novel drug targets for Parkinson's disease (PD) using genomic data from 3,000 patients in 23andMe's PD community. 23andMe will receive $10 million up front and is eligible for $50 million in milestones.

23andMe spokesperson Steve Cooper said the deal is the first among as many as eight tie-ups with pharmas and biotechs that it intends to announce in the coming months. Spokesperson Jackie Kahn declined to say what company will perform whole genome sequencing of the patients. ...